A Phase III trial demonstrated that the oral recombinant salmon calcitonin tablet OSTORA achieved superior efficacy to nasal calcitonin while showing equivalent safety. This offers a promising new treatment option for postmenopausal osteoporosis patients who have limited options due to side effects or poor tolerance.
The LuCED test uses 3D imaging to accurately detect cancer cells in sputum samples from high-risk individuals. This approach can significantly lower the number of false positive cases, making mass screening programs more feasible and cost-effective.
Euthymics Bioscience presents Phase II clinical data demonstrating the efficacy of EB-1010, a next-generation antidepressant, in treating major depressive disorder. The study showed significant improvements in depression symptoms and anhedonia, with a favorable safety profile.
Peregrine's PS-targeting antibody bavituximab reactivates the immune system to attack and destroy cancer cells, potentially working synergistically with multiple therapies. The company plans to initiate two new Phase II trials in refractory and front-line lung cancer patients by mid-year.
The study supports the utility of Chronix's serum DNA tests to predict clinical status and monitor disease activity in multiple sclerosis. The findings show that the approach can differentiate periods of active disease attacks from stable periods, providing a real-time measure of disease activity.
Researchers at Duke University found that Peregrine's PS-targeting antibodies can block the CCR5 receptor, a key portal for HIV to gain entry into blood cells. The study showed potent ability to induce specific effects that impact viruses, inducing β-chemokines to block HIV entry.
A recent study published in Leukemia suggests that genetic changes in response to environmental toxins may contribute to the development of multiple myeloma. The study found associations between specific DNA sequence variations and an increased risk of bone disease in myeloma patients.
The Veritide Ceeker portable bacterial detection device has been shown to accurately identify anthrax spores and distinguish them from hoax substances. With results produced in minutes, the device enables first responders to rapidly determine whether a situation is a nuisance or a major threat to public health.
A study in Zoonoses and Public Health confirms Chronix's potential for early disease detection, identifying signature sequences in serum DNA before clinical symptoms appear. The findings advance the company's ability to apply these results to laboratory tests for routine clinical use.
Preclinical studies highlight PS-targeting antibodies' ability to reverse immune suppressing effects of tumors, change tumor microenvironment, and mobilize immune cells. These findings suggest that PS-targeting antibodies facilitate a cytokine shift in the tumor environment, encouraging multiple types of immune system cells to mount an...
Researchers found that bavituximab, a PS-targeting antibody, can cure lethal virus infections in animal models of cytomegalovirus and Lassa fever. The drug showed potent anti-viral activity and may represent a new class of drugs for treating viral infections.
Researchers with Bank On A Cure identified genetic pathways associated with venous thromboembolisms in patients treated with thalidomide for multiple myeloma. These findings may lead to screenings and tailored interventions to prevent blood clots, as well as the development of new treatments.
A 24-week multi-center, placebo-controlled phase III trial demonstrated Contrave's superiority in weight loss compared to placebo. Patients taking Contrave experienced an average excess of 7% weight loss from baseline, while those on the placebo saw only 1% weight loss.